Foresee Pharmaceuticals Co., Ltd.

6576

TW0006576002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
83.5 ^TWD	-.--%		-14.27%	-13.20%

06-24	Foresee Pharmaceuticals Co., Ltd. announced a financing transaction	CI
05-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

AnForesee Pharmaceuticals Co., Ltd. Announces the Resignation of Ben Chien as Chief Strategy Officer

March 25, 2021 at 11:34 am

AnForesee Pharmaceuticals Co., Ltd. announced the resignation of Ben Chien as Chief Strategy Officer. Effective date is March 25, 2021.

Latest news about Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd. announced a financing transaction	06-23	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Foresee Pharmaceuticals Co., Ltd. Appoints Chris Liang as Accounting Officer	05-03	CI
Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive $7.841 million in funding	05-02	CI
Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020	04-30	CI
Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study	04-01	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes, Effective March 31, 2024	03-15	CI
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan	12-01	CI
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment	11-29	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA	16/10/23	CI
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients	13/10/23	CI
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	30/09/23	CI
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039	29/08/23	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee	14/08/23	CI
Foresee Pharmaceuticals to Present Allergic Asthma Study at European Medical Conference	26/07/23	MT
Foresee Pharmaceuticals Co., Ltd. Appoints Ben Liu as Audit Committee Member	01/06/23	CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director	01/06/23	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes	14/04/23	CI
Foresee Pharmaceuticals Co., Ltd. Announces the Primary Endpoint Data FP-025 in an Allergic Asthma Phase 2A Trial	04/04/23	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/02/23	CI
Foresee Pharmaceuticals Co., Ltd. Announces Change of its Senior Vice President of Clinical Development and Program Lead	17/02/23	CI

Chart Foresee Pharmaceuticals Co., Ltd.

Duration

Period

More charts

Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Foresee Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

83.5 TWD

Average target price

153 TWD

Spread / Average Target

+83.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FORESEE PHARMACEUTICALS CO., LTD.	-13.20%	349M
MODERNA, INC.	+19.41%	45.51B
IQVIA HOLDINGS INC.	-8.62%	38.52B
LONZA GROUP AG	+38.65%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research

Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

Biotechnology & Medical Research

AnForesee Pharmaceuticals Co., Ltd. Announces the Resignation of Ben Chien as Chief Strategy Officer

Latest news about Foresee Pharmaceuticals Co., Ltd.

Chart Foresee Pharmaceuticals Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Foresee Pharmaceuticals Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research